...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of experimental & clinical cancer research : >Accomplishments and perspectives of immunological interventions in lymphoproliferative disorders.
【24h】

Accomplishments and perspectives of immunological interventions in lymphoproliferative disorders.

机译：淋巴细胞增生性疾病免疫干预的成就和观点。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The purpose of this review is to consider evidences accumulated in the last few years which might lead to a new therapeutic strategy for lymphoproliferative disorders. Tumor-targeted and immunologically designed therapy has already started. Clinical effectiveness also includes the primary and secondary prevention of these malignancies. The fortifying of body's defense through vaccination as primary prevention with tumor-specific cell surface antigen, has been seen over the past few years, and will lead to health patient's improvement. Data collected from clinical trials and in vitro analysis indicated that the immune system of patients could recognize and eliminate neoplastic cells while sparing normal cells. In B-cell lymphomas and myelomas, the tumor-idiotype (Id) produced by a single B-cell clone, has been used for vaccination. Therapeutic Id vaccination used two types of antigen-presenting cells as natural adjuvants for the induction of antigen-specific T cell response. Dendritic cells (DCs)--basedvaccines are under active investigation and are entering clinical evaluation. Current research focuses on optimization of DCs source, choice and loading of antigen, mode of injection, as well as immune monitoring. Some preliminary results were obtained and no significant side effects of dendritic cells vaccination of lymphoma and myeloma patients have so far been reported. The over-estimation of clinical effectiveness, at this moment, is still limited by the small number of patients included in this kind of treatment. The challenge for the future will be to extend these early results to reproducible vaccination strategy according to current standards of good clinical practice (GCP).
机译：这篇综述的目的是考虑最近几年积累的证据，这些证据可能会导致新的淋巴增生性疾病治疗策略。肿瘤靶向和免疫学设计的治疗方法已经开始。临床有效性还包括对这些恶性肿瘤的一级和二级预防。通过接种疫苗来增强身体防御能力是肿瘤特异性细胞表面抗原的主要预防方法，这在过去几年中已经见到，并将导致健康患者的进步。从临床试验和体外分析中收集的数据表明，患者的免疫系统可以识别和消除肿瘤细胞，同时保留正常细胞。在B细胞淋巴瘤和骨髓瘤中，由单个B细胞克隆产生的肿瘤独特型（Id）已用于疫苗接种。治疗性Id疫苗接种使用两种类型的抗原呈递细胞作为天然佐剂，用于诱导抗原特异性T细胞应答。基于树突状细胞（DC）的疫苗正在积极研究中，并正在进入临床评估阶段。当前的研究集中在DC来源的优化，抗原的选择和负载，注射方式以及免疫监测方面。获得了一些初步结果，迄今为止，尚未报道过对淋巴瘤和骨髓瘤患者进行树突细胞疫苗接种的重大副作用。目前，对这种临床治疗方法的高估仍然受到少数患者的限制。未来的挑战将是，根据当前的良好临床实践（GCP）标准，将这些早期结果扩展到可重现的疫苗接种策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号